Futura Medical plc

("Futura" or the "Company")

Remuneration of Non-Executive Directors and Total Voting Rights

17 January 2024

Futura Medical plc (AIM: FUM) (the "Company"), the pharmaceutical company developing innovative sexual health products, announces the issue of 43,500 new ordinary shares of 0.2 pence each ("Ordinary Shares") in respect of the 2023 remuneration of its Non-Executive Directors.

Remuneration of Non-Executive Directors

In accordance with the terms of their service agreements, the Non-Executive Directors receive 25 per cent of their remuneration in the form of Ordinary Shares which are usually  in January following the period end. For 2023, these were issued at 51.50 pence per share, being the average closing mid-market price of the last 10 trading days of 2022 (as announced via RNS on 12 January 2023).

The 43,500 new Ordinary Shares shall rank pari passu with the existing issued Ordinary Shares of the Company and have been issued to the following Non-Executive Directors:

In addition, 19,913 shares have been issued to John Clarke.  John Clarke was a Non-Executive Director until July 2023 and these shares represent 25 per cent of his pro-rata remuneration for the period January to July 2023 in accordance with his service agreement.

The shares element of the Non-Executive Directors' remuneration for 2024 will be awarded at 27.10 pence per Ordinary Share, being the average closing mid-market price of the last 10 trading days of 2023. The Non-Executive Directors will receive these shares in January 2025.

Total Voting Rights

Application has been made to the London Stock Exchange and it is anticipated that trading of the new Ordinary Shares will commence on AIM at 8:00am on 22 January 2024.

Immediately following the above issue, the Company will have 301,449,451 ordinary shares in issue, each carrying one voting right. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 301,449,541 and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Further details are contained within the notifications below, made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014. Full details of the Non-Executive Directors' remuneration will be included in the Company's Annual Report & Accounts.

ENDS

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [email protected]
Tel: +44 (0) 1483 685 670
www.Futuramedical.com

Nominated Adviser and Sole Broker:
Liberum
Phil Walker /Benjamin Cryer
Tel: +44 (0) 20 3100 2000

For media enquiries please contact:

Optimum Strategic Communications

Nick Bastin / Jonathan Edwards / Elena Bates

Email: [email protected]

Tel: +44 (0) 203 950 9144

Notes to editors

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing innovative products based on its proprietary, transdermal DermaSys® technology.

MED3000, the Company's breakthrough treatment for erectile dysfunction ("ED") has a unique evaporative mode of action and is clinically proven as an effective topical treatment for adult men with ED, with a key claim of "Helps you get an erection within 10 minutes". Eroxon® is available Over the Counter ("OTC") without a doctor's prescription. www.eroxon.com.

MED3000 is being manufactured and commercialised under the brand name Eroxon® and has been granted marketing authorisation by the FDA in the US, CE marked in Europe, UKCA marked in the UK and is gaining regulatory approval in a growing number of countries across the world. Futura has commercial agreements with Haleon for the US market and Cooper Consumer Health for Europe.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com.